- Plans for complex launches in US which will give meaningful traction in FY24.
- India formulations business is likely to stabilise as the company has optically initiated restructuring of business by rationalising slow moving SKUs.
- Huge Pipeline of Innovative Products like Saroglitazar Magnesium, Desidustat, anti-malarial compound, biologics and 505(b)(2) specialty initiatives
- EBITDA Margin guidance of 20% is maintained by management.
- Total 25-30 launches planned in US for FY23.
- Launch of Revlimid and clearance of Moraiya plant provide good growth prospects.
- Expected spend on R&D is 7-8% of revenues.
- Gross Margins in Consumer Wellness Business will get better in the coming quarters.
| Subscribe To Our Free Newsletter |
